Market News

The U.S. Food and Drug Administration approved NERLYNX (neratinib) for the extended adjuvant treatment of early-stage, HER2-positive breast cancer in July 2017.
Excelera has announced the appointment of Lorrie A. Carr as its new CEO. Ms. Carr succeeds Jim Fox who retired effective April 2.
New FDA-approved therapy offers more options to patients with advanced type of skin cancer.
Company’s Clinical Expertise, Positive Patient Outcomes Garners Access to Limited Drug Distribution.
Collaboration Brings Technology Advancements to Specialty Pharmacy Marketplace to Deliver Better Outcomes, Quality, Efficiency and Cost Management.
Wui-Jin Koh, MD, will take on new leadership position at alliance of 27 leading cancer centers.
Industry-leading limited distribution drug access means ability to serve 98 percent of specialty members’ needs through both LDD and non-LDD medication.
Distribution expansion marks shift to clinically-proven safety provisions for nurses and pharmacists in burgeoning Hong Kong market.
Company Profile >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Contact Us
Terms & Conditions
MJH Associates >
Pharmacy Times
American Journal of Managed Care
MD Magazine
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2019
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.